Matica Biotechnology Inc.’s board of directors has appointed Yun Jeong Song, MD, as the company’s new chief executive officer to continue its expansion as a CDMO supporting the global cell and gene therapy industry.
 
Experience
 
Song joined the company effective April 1, 2021 after 3 years as CEO of ImmuneOncia Therapeutics, an international joint venture developing immuno-oncology therapies. She succeeds Byung Se So, PhD, who will remain with Matica Bio as an advisor.
 
Song’s background spans more than 20 years of basic research, patient care and biopharmaceutical industry leadership. Prior to ImmuneOncia Therapeutics, she held positions at the U.S. National Institutes of Health, Samsung, and Sanofi.
 
“I am very excited to lead Matica Bio, a scientifically sophisticated and ambitious company,” commented Song. “My goal is to further establish the company as a respected, reliable partner to our clients, and advance our continued global expansion in this very active and dynamic field of viral vector manufacturing. We are here to fully support our clients, providing the technology and know-how to help them deliver innovative drugs to patients worldwide.”
 
So remarked, “We are delighted to have Dr. Song join the company as CEO. Her demonstrated ability to drive the growth of an innovative drug development pipeline, advancing novel therapies to the clinic, will be extremely valuable in helping Matica Bio execute on our promise to clients who are delivering advanced therapies and vaccines to address unmet needs.”